#511
Re: Oryzon Genomics (ORY)
Hoy voy a ser optimista se calcula que entre el 1 y el 2% de la población tiene tlp. En Europa y EUA eso equivale a 27 millones de personas solo en estas regiones.
Pongamos que solo se trata a la mitad o menos pongamos a 10 millones , recordemos que no hay fármaco alguno en el mercado y menos sin efectos secundarios.
Y pondremos un beneficio anual para oryzon de solo 50€/año por paciente.
Nos da 500.000.000 millones
Faltaría asía Australia etc.
Final FDA meeting in September
Today I will be optimistic that between 1 and 2% of the population has BPD. In Europe and the US that equates to 27 million people in these regions alone.
Let's just treat half or less put to 10 million, remember that there is no drug on the market and less without side effects.
And we will put an annual benefit for Oryzon of only 50€/year per patient.
He gives us 500.000.000 million.
Australia would be missing etc...
Pongamos que solo se trata a la mitad o menos pongamos a 10 millones , recordemos que no hay fármaco alguno en el mercado y menos sin efectos secundarios.
Y pondremos un beneficio anual para oryzon de solo 50€/año por paciente.
Nos da 500.000.000 millones
Faltaría asía Australia etc.
Final FDA meeting in September
Today I will be optimistic that between 1 and 2% of the population has BPD. In Europe and the US that equates to 27 million people in these regions alone.
Let's just treat half or less put to 10 million, remember that there is no drug on the market and less without side effects.
And we will put an annual benefit for Oryzon of only 50€/year per patient.
He gives us 500.000.000 million.
Australia would be missing etc...
